drugset / Trial / NCT01223222
A Study to Evaluate Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) on Uncomplicated, Gram-positive, Skin Infection
RandomizedSingle-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of Lytixar™ applied topically to uncomplicated skin infections. Three dose levels of Lytixar™ (1%, 2% and 5%) versus placebo will be tested.
Timeline
- Start
- 2010-09
- Primary completion
- 2011-02
- Completion
- 2011-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | LTX-109 | Peptide | 1 % | Topical |
| Comparator | LTX-109 | Peptide | 2 % | Topical |
| Comparator | LTX-109 | Peptide | 5 % | Topical |